PMC:7408073 / 16-357 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":52,"end":76},"obj":"Body_part"},{"id":"T2","span":{"begin":177,"end":201},"obj":"Body_part"},{"id":"T3","span":{"begin":203,"end":206},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":" of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely o"}

{"project":"LitCovid-PubTator","denotations":[{"id":"4","span":{"begin":4,"end":7},"obj":"Gene"},{"id":"5","span":{"begin":8,"end":12},"obj":"Gene"},{"id":"6","span":{"begin":52,"end":57},"obj":"Gene"},{"id":"7","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"25","span":{"begin":240,"end":248},"obj":"Species"},{"id":"26","span":{"begin":261,"end":271},"obj":"Species"},{"id":"31","span":{"begin":249,"end":257},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Gene:59272"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"Gene:59272"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"Gene:5972"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:C000657245"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely o"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T2","span":{"begin":261,"end":269},"obj":"Disease"},{"id":"T3","span":{"begin":261,"end":265},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely o"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":58,"end":69},"obj":"Chemical"},{"id":"T2","span":{"begin":183,"end":194},"obj":"Chemical"},{"id":"T3","span":{"begin":203,"end":206},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":" of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely o"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":23,"end":108},"obj":"Sentence"},{"id":"T3","span":{"begin":110,"end":118},"obj":"Sentence"},{"id":"T4","span":{"begin":119,"end":326},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients\n\nAbstract\nThe article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely o"}